Decreased susceptibility to cephalosporins among gonococci? - Authors' reply

Catherine A. Ison; Katy Town; Chinelo Obi; Stephanie Chisholm; Gwenda Hughes; David M. Livermore; Catherine M. Lowndes

doi:10.1016/S1473-3099(14)70023-4

Decreased susceptibility to cephalosporins among gonococci? - Authors' reply

Catherine A. Ison, Katy Town, Chinelo Obi, Stephanie Chisholm, Gwenda Hughes, David M. Livermore, Catherine M. Lowndes

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	186-187
Number of pages	2
Journal	The Lancet Infectious Diseases
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/S1473-3099(14)70023-4
Publication status	Published - Mar 2014

Bibliographical note

Funding Information:
The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) was funded totally (2000–04) and partially (2005–10) by the Department of Health (England) and by Public Health England. DML has received personal fees from Allecra, Discuva; Pfizer, Curetis, Cycle Pharma, Cubist, Alere, Bioversys, Forest, Tetraphase, Wockhardt, Shionogi, and AOP Orphan; grants and personal fees from Achaogen, Adenium, Meiji, and AstraZeneca; grants, personal fees, and other support from GlaxoSmithKline; personal fees and non-financial support from Bruker; grants from VenatoRx, Merck, and Rokitan; and other support from Perkin Elmer. CAI has received funding from Merck for testing alternative antimicrobial agents. All other authors declare that they have no conflicts of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1473-3099(14)70023-4

Cite this

@article{c8bc6b986d29449eab80361f558c8794,

title = "Decreased susceptibility to cephalosporins among gonococci? - Authors' reply",

author = "Ison, {Catherine A.} and Katy Town and Chinelo Obi and Stephanie Chisholm and Gwenda Hughes and Livermore, {David M.} and Lowndes, {Catherine M.}",

note = "Funding Information: The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) was funded totally (2000–04) and partially (2005–10) by the Department of Health (England) and by Public Health England. DML has received personal fees from Allecra, Discuva; Pfizer, Curetis, Cycle Pharma, Cubist, Alere, Bioversys, Forest, Tetraphase, Wockhardt, Shionogi, and AOP Orphan; grants and personal fees from Achaogen, Adenium, Meiji, and AstraZeneca; grants, personal fees, and other support from GlaxoSmithKline; personal fees and non-financial support from Bruker; grants from VenatoRx, Merck, and Rokitan; and other support from Perkin Elmer. CAI has received funding from Merck for testing alternative antimicrobial agents. All other authors declare that they have no conflicts of interest.",

year = "2014",

month = mar,

doi = "10.1016/S1473-3099(14)70023-4",

language = "English",

volume = "14",

pages = "186--187",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - Decreased susceptibility to cephalosporins among gonococci? - Authors' reply

AU - Ison, Catherine A.

AU - Town, Katy

AU - Obi, Chinelo

AU - Chisholm, Stephanie

AU - Hughes, Gwenda

AU - Livermore, David M.

AU - Lowndes, Catherine M.

N1 - Funding Information: The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) was funded totally (2000–04) and partially (2005–10) by the Department of Health (England) and by Public Health England. DML has received personal fees from Allecra, Discuva; Pfizer, Curetis, Cycle Pharma, Cubist, Alere, Bioversys, Forest, Tetraphase, Wockhardt, Shionogi, and AOP Orphan; grants and personal fees from Achaogen, Adenium, Meiji, and AstraZeneca; grants, personal fees, and other support from GlaxoSmithKline; personal fees and non-financial support from Bruker; grants from VenatoRx, Merck, and Rokitan; and other support from Perkin Elmer. CAI has received funding from Merck for testing alternative antimicrobial agents. All other authors declare that they have no conflicts of interest.

PY - 2014/3

Y1 - 2014/3

UR - http://www.scopus.com/inward/record.url?scp=84894319370&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(14)70023-4

DO - 10.1016/S1473-3099(14)70023-4

M3 - Letter

C2 - 24571973

AN - SCOPUS:84894319370

SN - 1473-3099

VL - 14

SP - 186

EP - 187

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 3

ER -

Decreased susceptibility to cephalosporins among gonococci? - Authors' reply

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this